BIO vs. RPRX: Bio-Rad Laboratories vs. Royalty Pharma Stock Comparison

Company Profile

Bio-Rad Laboratories (BIO) and Royalty Pharma (RPRX) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIO is classified in Life Sciences Tools & Services while RPRX is classified in Pharmaceuticals.

Bio-Rad Laboratories (BIO) has more than two decades of public-market history since February 27, 1980, whereas Royalty Pharma (RPRX) listed on June 16, 2020 and has a much shorter record to draw on.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Bio-Rad Laboratories (BIO) at 14.27% and Royalty Pharma (RPRX) at 12.09% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Both Bio-Rad Laboratories (BIO) at 39.45% and Royalty Pharma (RPRX) at 25.70% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Royalty Pharma (RPRX) at 81.32% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO) at 11.82%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both Bio-Rad Laboratories (BIO) at 0.65% and Royalty Pharma (RPRX) at 5.06% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Royalty Pharma (RPRX) reports EPS growth of 23.09%, ranked against its industry; Bio-Rad Laboratories (BIO) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Bio-Rad Laboratories (BIO) at 3.18 keeps current ratio within its industry’s typical mid-range, while Royalty Pharma (RPRX) at 1.29 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for RPRX.

Bio-Rad Laboratories (BIO) at 0.18 carries an industry-typical debt-to-equity mix, while Royalty Pharma (RPRX) at 0.88 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Bio-Rad Laboratories (BIO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Royalty Pharma (RPRX) reports a yield of 1.37%, ranking against industry peers normally.

Bio-Rad Laboratories (BIO) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Royalty Pharma (RPRX) reports a payout of 60.46%, ranking against industry peers normally.

Dividend Metrics

Valuation

Bio-Rad Laboratories (BIO) at 10.14 sits in the cheaper P/E ratio quartile, while Royalty Pharma (RPRX) at 43.99 sits in the richer quartile — a clear split in what investors pay for each dollar of trailing earnings.

On P/S ratio, both Bio-Rad Laboratories (BIO) at 3.96 and Royalty Pharma (RPRX) at 14.79 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Bio-Rad Laboratories (BIO) at 1.35 sits in the lower P/B ratio quartile against book while Royalty Pharma (RPRX) at 4.39 is valued near its industry’s middle — BIO is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics